Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, place
6 hours ago
- #alopecia areata
- #TYK2 inhibitor
- #clinical trial
- Deucravacitinib, an oral selective allosteric TYK2 inhibitor, was evaluated in a phase II trial for alopecia areata.
- Patients were randomized to placebo, 6 mg once daily, or 6 mg twice daily doses; placebo groups switched to active treatment after 24 weeks.
- The primary endpoint was change in SALT score at Week 24, with no meaningful differences observed between deucravacitinib and placebo groups.
- Secondary endpoints, including SALT50 and AAIA scores, also showed no significant differences.
- The trial was terminated early due to a strategic decision, not because of efficacy or safety findings, without affecting study power.
- No new safety signals were identified, and the safety profile was consistent with known data.
- Conclusions indicate that TYK2 inhibition with deucravacitinib may not play a major role in hair regrowth for alopecia areata.